Indications to Start Rasburicase
Rasburicase should be started in high-risk patients for tumor lysis syndrome (TLS) as initial prophylaxis, in intermediate-risk patients who develop hyperuricemia despite allopurinol, and in any patient with preexisting hyperuricemia ≥7.5 mg/dL (450 µmol/L). 1
Risk Stratification Framework
Before determining rasburicase indication, classify patients into risk categories based on three domains:
High-Risk Patients (Rasburicase Indicated)
Host factors:
- Pre-existing renal impairment or renal infiltration by malignancy
- Obstructive uropathy
- Hyperuricemia >8 mg/dL (children) or >10 mg/dL (adults)
- Dehydration
Disease factors:
- Burkitt's lymphoma or high-grade lymphomas
- Acute lymphoblastic leukemia in adults
- Advanced T-cell ALL in pediatric patients
- Bulky disease (especially bulky SCLC with massive liver metastases)
- Metastatic germ cell tumors
- LDH >2× upper normal limit
Therapy factors:
- Intensive polychemotherapy (cisplatin, cytarabine, etoposide, methotrexate) 2
Intermediate-Risk Patients (Conditional Rasburicase Use)
Start rasburicase if hyperuricemia develops despite prophylactic allopurinol treatment. Otherwise, begin with allopurinol plus hydration. 1
Low-Risk Patients (Allopurinol Sufficient)
Use allopurinol, hydration, and close monitoring. Rasburicase not indicated. 2
Specific Clinical Scenarios
Preexisting Hyperuricemia
For patients presenting with uric acid ≥7.5 mg/dL (450 µmol/L), rasburicase is preferred over allopurinol because allopurinol only prevents new uric acid formation and cannot reduce existing elevated levels. 1 This is critical when chemotherapy cannot be delayed.
Established TLS (Laboratory or Clinical)
Rasburicase is recommended for treatment of hyperuricemia associated with laboratory TLS (LTLS) or clinical TLS (CTLS). 1 This represents therapeutic rather than prophylactic use.
Previous TLS History
Patients who experienced TLS during prior treatments should receive rasburicase prophylaxis for subsequent chemotherapy cycles. Consider nephrology consultation before restarting therapy. 2
Dosing and Administration
Standard dose: 0.20 mg/kg/day IV over 30 minutes, starting at least 4 hours before chemotherapy, continuing 3-5 days. 2
Alternative approaches supported by evidence:
- Lower doses (0.10-0.15 mg/kg) may be effective for prevention 1
- Single fixed doses (3-7.5 mg) have shown efficacy in adults 3, 4, 5
- Duration guided by uric acid monitoring; stop when levels undetectable or very low 1
Absolute Contraindications
Do not use rasburicase in:
- G6PD deficiency (risk of hemolysis and methemoglobinemia) 1, 6
- Pregnancy or lactation 6
- Known hypersensitivity/anaphylaxis to rasburicase 1
Screen high-risk populations: African American, Mediterranean, Southeast Asian descent. Obtain thorough history of drug-induced hemolytic anemia and definitive G6PD testing when possible. 1
Critical Monitoring Requirements
Blood samples for uric acid must be immediately placed on ice and analyzed within 4 hours to prevent ex vivo enzymatic degradation by rasburicase, which causes falsely low readings at room temperature. 1, 6
For high-risk patients, monitor every 12 hours for first 3 days:
- Uric acid, potassium, phosphorus, calcium
- Creatinine, BUN
- LDH 2
Common Pitfalls to Avoid
Do not combine rasburicase with allopurinol - causes xanthine accumulation and removes substrate for rasburicase activity 2
Do not alkalinize urine when using rasburicase - increases calcium phosphate precipitation risk without added benefit 2
Do not use in low-risk patients - guidelines are frequently violated in practice, leading to unnecessary costs without clinical benefit 7
Start rasburicase before chemotherapy - ideally 4-48 hours prior, though rapid uric acid reduction allows earlier chemotherapy initiation if needed 2, 6
The evidence strongly supports risk-stratified use of rasburicase, with the highest quality data demonstrating superior uric acid control compared to allopurinol in high-risk populations, reducing dialysis requirements from 16% to 2.6% in comparative studies. 2